Loading
A phase 1 trial of [Ac-225]RTX-2358 run by Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, now recruiting.
Safety and Preliminary Efficacy of [177Lu]Lu-RTX-2358 Combined With Immune Checkpoint Inhibitors in Patients With FAP-positive Metastatic Non-Small Cell Lung Cancer is a phase 1 interventional study registered as NCT07689643 by Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, with 36 participants planned, started 2026-04-28. Conditions recorded: Metastatic Non-small Cell Lung Cancer. Interventions recorded: [177Lu]Lu-RTX-2358.
Shares [Ac-225]RTX-2358, Ratio Therapeutics and the tag pipeline.
Shares Non-small-cell lung cancer and the tag pipeline.
Shares Non-small-cell lung cancer and the tag pipeline.
Shares Non-small-cell lung cancer and the tag pipeline.
Shares Non-small-cell lung cancer and the tag pipeline.
Shares Non-small-cell lung cancer and the tag pipeline.
Shares Non-small-cell lung cancer and the tag pipeline.
Shares Non-small-cell lung cancer and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/